Discarding Occam’s Razor: Atypical Bruising in Severe Hemophilia A

Di Paola J Montgomery RR Gill JC Flood V. Hemophilia and von Willebrand disease. In Orkin S Nathan D Ginsburg D Look AT Fisher D Lux S , eds. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2015.

Carr ME Jr Tortella B. Emerging and future therapies for hemophilia. J Blood Med. 2015;6:245.

Hoyer LW Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol. 1994;31(2 suppl 4):1-5.

Lusher JM Arkin S Abildgaard CF Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A—safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328:453-459.

Gupta M Lillicrap D Stain AM Friedman KD Carcao MD. Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease. Pediatr Blood Cancer. 2011;57:1081-1083.

Miller CH Hilgartner MW Harris MB Bussel JB Aledort LM. Concurrence of von Willebrand’s disease and hemophilia A: implications for carrier detection and prevalence. Am J Med Genet. 1986;24:83-94.

Casonato A Pontara E Sartorello F Gemmati D Cattini MG Girolami A. Combined hemophilia A and type 2 von Willebrand’s disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor. Haematologica. 2001;86:1110-1111.

Asatiani E Kessler CM. Multiple congenital coagulopathies co-expressed with von Willebrand’s disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature. Haemophilia. 2007;13:685-696.

Lindsay H Bergstrom K Srivaths L. Co-inheritance of mild hemophilia A and heterozygosity for type 2N von Willebrand disease: a diagnostic and therapeutic challenge. Pediatr Blood Cancer. 2014;61:1888-1890.

Daidone V Pontara E Boscaro F Cattini MG Milan M Casonato A . Haemostatic patterns and bleeding scores of a genetically characterised Italian family with combined haemophilia A and type 1 von Willebrand disease. Blood Coagul Fibrinolysis. 2017; 28:230–233.

Gill JC Castaman G Windyga J Kouides P Ragni M Leebeek F Obermann-Slupetzky O Chapman M Fritsch S Pavlova BG Presch I Ewenstein B . Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015 Oct 22;126(17):2038-46